Literature DB >> 12869888

Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options.

Sammy Saab1, Victor Wang.   

Abstract

Hepatitis C virus (HCV) related cirrhosis is the most common indication for orthotopic liver transplantation (OLT). Updated data suggest worse long-term outcomes for those transplanted with HCV than those transplanted for other indications. Re-infection with HCV post-OLT is universal, therefore diagnosis of recurrence should be based on histological findings in the setting of persistent viremia. Variables associated with worse outcome of recurrent disease include early recurrence, degree of immunosuppression, and donor age. Antiviral therapy has been used in the prevention and treatment of recurrent disease, and can be initiated prior to transplantation, prophylactically after transplantation, and during recurrence. Preliminary studies of pre-transplantation treatment demonstrate virological responses, but tolerance is common. Higher efficacy has been associated with combination therapy for recurrent disease. Adverse effects limit its widespread use.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869888     DOI: 10.1097/00004836-200308000-00013

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  6 in total

1.  Quantification of C4d deposition and hepatitis C virus RNA in tissue in cases of graft rejection and hepatitis C recurrence after liver transplantation.

Authors:  Alice Tung Wan Song; Evandro Sobroza de Mello; Venâncio Avancini Ferreira Alves; Norma de Paula Cavalheiro; Carlos Eduardo Melo; Patricia Rodrigues Bonazzi; Fatima Mitiko Tengan; Maristela Pinheiro Freire; Antonio Alci Barone; Luiz Augusto Carneiro D'Albuquerque; Edson Abdala
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-02-13       Impact factor: 2.743

2.  Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.

Authors:  Alice Tung Wan Song; Rodolphe Sobesky; Carmen Vinaixa; Jérôme Dumortier; Sylvie Radenne; François Durand; Yvon Calmus; Géraldine Rousseau; Marianne Latournerie; Cyrille Feray; Valérie Delvart; Bruno Roche; Stéphanie Haim-Boukobza; Anne-Marie Roque-Afonso; Denis Castaing; Edson Abdala; Luiz Augusto Carneiro D'Albuquerque; Jean-Charles Duclos-Vallée; Marina Berenguer; Didier Samuel
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

3.  Publicly funded pegylated interferon-alpha treatment in British Columbia: disparities in treatment patterns for people with hepatitis C.

Authors:  Priscilla C Hsu; Jane A Buxton; Andrew W Tu; Warren D Hill; Amanda Yu; Mel Krajden
Journal:  Can J Gastroenterol       Date:  2008-04       Impact factor: 3.522

4.  Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C.

Authors:  Sammy Saab; Justin Rheem; Melissa A Jimenez; Tiffany M Fong; Michelle H Mai; Caterina A Kachadoorian; Negin L Esmailzadeh; Sherona N Bau; Susan Kang; Samantha D Ramirez; Jonathan Grotts; Gina Choi; Francisco A Durazo; Mohammed M El-Kabany; Steven-Huy B Han; Ronald W Busuttil
Journal:  J Clin Transl Hepatol       Date:  2017-05-14

5.  The impact of immunosuppressant therapy on the recurrence of hepatitis C post-liver transplantation.

Authors:  Abdulkareem M Albekairy; Wesam S Abdel-Razaq; Abdulmalik M Alkatheri; Tariq M Al Debasi; Nouf E Al Otaibi; Amjad M Qandil
Journal:  Int J Health Sci (Qassim)       Date:  2018 Jul-Aug

6.  Antihepatitis C virus therapy in liver transplanted patients.

Authors:  Antonino Picciotto
Journal:  Ther Clin Risk Manag       Date:  2006-03       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.